Atogepant 60 mg vs rimegepant and galcanezumab for episodic migraine prevention has superior efficacy, with comparable safety ...

HealthDay News — Approved label populations for new drugs are broader than trial populations overall, according to a study published online July 8 in the Annals of Internal Medicine.